Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource, 1 online resource.
Sprache
Englisch

Erschienen in
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study ; volume:46 ; number:9 ; day:28 ; month:6 ; year:2023 ; pages:835-845 ; date:9.2023
Drug safety ; 46, Heft 9 (28.6.2023), 835-845, 9.2023

Urheber
Cornblath, David R.
van Doorn, Pieter A.
Hartung, Hans-Peter
Merkies, Ingemar S. J.
Katzberg, Hans D.
Hinterberger, Doris
Clodi, Elisabeth
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s40264-023-01326-z
URN
urn:nbn:de:101:1-2023110607462136677510
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:49 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Cornblath, David R.
  • van Doorn, Pieter A.
  • Hartung, Hans-Peter
  • Merkies, Ingemar S. J.
  • Katzberg, Hans D.
  • Hinterberger, Doris
  • Clodi, Elisabeth
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?

Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?

How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast

How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy

Clinical and neurophysiological correlation in axonal and demyelinating polyneuropathy

Clinical and neurophysiological correlation in axonal and demyelinating polyneuropathy

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV

Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy

Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy

Tubercular Meningitis with Acute Inflammatory Demyelinating Polyneuropathy—Trigger or Chance

Tubercular Meningitis with Acute Inflammatory Demyelinating Polyneuropathy—Trigger or Chance

Verbundene Objekte